Navigation Links
New funds for Rice, M.D. Anderson program
Date:11/17/2009

The Howard Hughes Medical Institute (HHMI) today committed four years' worth of funding for an innovative biomedical training program between Rice University and the University of Texas M.D. Anderson Cancer Center.

The unique program -- founded with a 2006 HHMI grant -- capitalizes on the strengths of Rice's top-10-ranked bioengineering program and M.D. Anderson's internationally renowned clinical programs. The training gives incoming graduate students an early opportunity to see how laboratory research is translated into clinical practice. HHMI today pledged $700,000 to renew the program for four years, bringing its total commitment to just over $1.5 million.

"We've developed a summer 'boot camp' for Rice's incoming bioengineering students," said Rebecca Richards-Kortum, the program's principal investigator and the Stanley C. Moore Professor of Bioengineering at Rice. "They spend the summer before graduate school taking a course in anatomy and pathology, and going on clinical rounds in different specialties at M.D. Anderson. They get a firsthand look at what it's like to do translational research in a medical center, and they choose co-advisers for their own translational research thesis."

Richards-Kortum, an investigator in Rice's new BioScience Research Collaborative, said the HHMI funding renewal will allow Rice and M.D. Anderson to continue the existing program and to expand it to include students from M.D. Anderson's Department of Imaging Physics.

"We are very excited about continuing this program with our colleagues at Rice. These students are truly exceptional and this program provides them a head start on getting involved in translational research," said John Hazle, chairman of Imaging Physics at M. D. Anderson. "Expanding this program to include students from our world-class graduate program in medical physics with the Rice students combines our expertise in engineering and natural science to address translational research questions together."

The program addresses a growing awareness of the need to better translate scientific discoveries from laboratories into clinical applications that benefit patients.

HHMI's "Med to Grad" initiative is designed to address this disconnect by supporting innovative graduate programs that introduce Ph.D. students to the world of clinical medicine.

Rice and M.D. Anderson's program, "Translational Bioengineering for Cancer Diagnostics and Therapeutics," was one of 13 programs HHMI funded under its initial round of "Med to Grad" grants in 2006. HHMI announced 23 new awards for the program this week. The Rice-M.D. Anderson program was one of 11 programs to earn a renewal.


'/>"/>

Contact: David Ruth
druth@rice.edu
713-348-6327
Rice University
Source:Eurekalert

Related medicine news :

1. New Jersey Soccer Coach Hopes for Thanksgiving Miracle for Local Mom - Tournament to Raise Funds for Her Critically Ill Baby
2. Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly
3. Congressman Fattah Supports Legislation to Address More Funds for Pancreatic Cancer Research
4. Federal stimulus funds support studies geared to improving HIV care and prevention
5. Smith & Nephew Orthopaedics Donates Inaugural Funds to COTA Grants Program
6. Pendleton by Jill Rappaport Launches In Store; Raises Funds for Animal Health and Wellness and Indian College Fund
7. Bill & Melinda Gates Foundation Funds 76 New Ideas to Improve Global Health, From Chewing Gum to Chocolate
8. Leahy Secures Funds to Support Adoption of Electronic Prescribing in Vermont
9. $4 million NCI grant funds comparative effectiveness research at Southwest Oncology Group
10. deVere and Partners Raises Funds for Geneva Children in Need
11. Stimulus Funds Establish Seattle as Hub of Comparative-Effectiveness Research in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: